ClinicalTrials.gg
Active, not recruitingNCT03361735Updated Apr 9, 2026Results posted

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

A Phase 2 interventional study of Leuprolide Acetate and Goserelin Acetate in Prostate Adenocarcinoma, sponsored by City of Hope Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by City of Hope Medical Center · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This phase 2 trial studies radium Ra 223 dichloride, hormone therapy and stereotactic body radiation in treating patients with prostate cancer that has spread to other places in the body. Radium Ra 223 dichloride contains a radioactive substance that collects in the bone and gives off radiation that may kill cancer cells. Hormone therapy using leuprolide acetate or goserelin acetate may fight prostate cancer by lowering the amount of testosterone the body makes. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Giving radium Ra 223 dichloride, hormone therapy and stereotactic body radiation may work better at treating prostate cancer.

Read the detailed description

PRIMARY OBJECTIVES:

I. To assess the time to treatment failure (TTF) in patients who initiated the protocol regimen of androgen deprivation therapy (ADT) with stereotactic body radiation therapy (SBRT) and radium Ra 223 dichloride and received at least one dose with radium Ra 223 dichloride.

SECONDARY OBJECTIVES:

I. To assess the safety of adding radium Ra 223 dichloride to SBRT and ADT in patients with oligometastatic castration sensitive prostate cancer.

II. To assess the prostate-specific antigen (PSA) and overall response rate (ORR) after 6 cycles of radium Ra 223 dichloride (cycle 8 day 1).

III. To assess the progression-free survival (PFS) in patients with oligometastatic castration sensitive prostate cancer who initiated the protocol regimen of ADT with SBRT and radium Ra 223 dichloride and received at least one dose of radium Ra 223 dichloride.

IV. To assess time to bone specific PFS in patients with oligometastatic castration sensitive prostate cancer who initiated the protocol regimen of ADT with SBRT and radium Ra 223 dichloride and received at least one dose of radium Ra 223 dichloride.

V. To assess overall survival, complete response rate, duration of response, and duration of overall complete response and duration of stable disease in patients with oligometastatic castration sensitive prostate cancer who initiated the protocol regimen of ADT with SBRT and radium Ra 223 dichloride.

VI. To assess long-term toxicities during 5-year follow-up in patients with oligometastatic castration sensitive prostate cancer who initiated the protocol regimen of ADT with SBRT and radium Ra 223 dichloride and received at least one dose of radium Ra 223 dichloride.

TERTIARY OBJECTIVES:

I. To perform exploratory analysis of primary or metastatic tumor mutation patterns in this study population at baseline.

II. To identify immune system factors in the blood that change during the course of ADT-radiotherapy for metastatic prostate cancer.

III. To describe the rate of normalization of the total alkaline phosphatase level (defined as a return to a value within the normal range) at the end of protocol therapy in patients oligometastatic castration sensitive prostate cancer with total alkaline phosphatase values above the upper limit of the normal range at baseline.

OUTLINE:

Beginning 4 weeks (28 days) prior to radiation therapy, patients receive leuprolide acetate or goserelin acetate, or degarelix for up to 32 weeks. Patients also undergo 3-5 fractions of SBRT every 40 hours over 7-21 days beginning on day 1 of course 1, and receive radium Ra 223 dichloride intravenously (IV) over 1 minute on day 1 of courses 2-7. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for up to 5 years.

02

Conditions studied

  • Prostate Adenocarcinoma

Keywords

  • PSA Level Greater than or Equal to 0.2
  • Stage IV Prostate Adenocarcinoma AJCC v7
03

In context

Lead sponsor

City of Hope Medical Center is the lead sponsor of 677 studies on the registry; 181 are open to participants now.

Of its 31 completed or terminated interventional studies of FDA-regulated products, 12 (39%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented of participant and/or legally authorized representative
  • Agreement to provide archival primary or tumor tissue if available
  • (ECOG) =\< 2
  • > 12 months
  • Histologic diagnosis of prostate adenocarcinoma

    * Pure small cell carcinoma will be excluded; however, component of neuroendocrine /small cell differentiation will be allowed provided that adenocarcinoma constitutes majority of the tissue specimen

  • Stage M1

    * Metastatic disease can be documented by bone scan or computed tomography (CT) scan or magnetic resonance imaging (MRI) or positron emission tomography (PET)/CT or the combination of these tests

  • Up to 4 metastatic lesions:

    • Must have at least 1 bone lesion AND each non-visceral lesion should be less than 5 cm
    • Visceral lesions will be limited to one lung lesion (\< 2 cm) or one lymph node; no liver lesions allowed; lymph nodes allowed provided they are not in a field of prior radiation, and if amenable to SBRT (to be reviewed by principal investigator [PI])
  • Two lesions can be in close proximity (i.e. within 5 cm of each other) if they meet radiation SBRT normal tissue toxicity requirements
  • If have untreated primary prostate cancer: must undergo debulking prostatectomy
  • If had prior definitive radiation therapy to the prostate: no evidence of locally persistent or recurrent prostate cancer on digital rectal exam (DRE) and imaging studies (CT or MRI); retreatment to local residual-recurrent disease will result in potential eligibility to be reviewed by PI on a case-by-case basis
  • Does not have castration resistant disease

    * Castration resistance defined as progression of disease despite serum testosterone level of \< 50 ng/dL

  • PSA >= 0.2 prior to start of androgen deprivation treatment
  • Initiated 28 (+ 7) days of androgen deprivation therapy (ADT) prior to day 1 of protocol therapy

    * Only luteinizing hormone-releasing hormone (LHRH) agonist/antagonist treatment is considered ADT, bicalutamide or other antiandrogens used alone do not count

  • May have received prior hormonal therapy in the context of definitive treatment of a primary tumor

    * Patients may have had one prior systemic non-chemotherapeutic treatment (i.e. immunotherapy, receptor tyrosine kinase inhibitor, antiangiogenic agent, differentiating agent) for recurrent or metastatic disease

  • Must have refused standard of care chemotherapy for metastatic disease
  • Recovered from all acute side-effects (except alopecia) related to previous systemic therapy
  • (ANC) >= 1,500/mm\^3 (to be performed within 14 days prior to day 1 of protocol therapy)

    * NOTE: growth factor support is not permitted to normalize baseline ANC parameters, however subsequent growth factor administration is permitted as standard supportive care

  • >= 100,000/mm\^3 (to be performed within 14 days prior to day 1 of protocol therapy)

    * NOTE: transfusion of blood products are not allowed to normalize baseline blood parameters, however subsequent transfusions are allowed per standard supportive care guidelines

  • (HgB) >= 9.0 g/dL (to be performed within 14 days prior to day 1 of protocol therapy)

    * NOTE: transfusion of blood products are not allowed to normalize baseline blood parameters, however subsequent transfusions are allowed per standard supportive care guidelines

  • Total serum =\< 2 x (ULN) (to be performed within 14 days prior to day 1 of protocol therapy)
  • (AST) =\< 2.5 x ULN (to be performed within 14 days prior to day 1 of protocol therapy)
  • Alanine aminotransferase (ALT) =\< 2.5 x ULN (to be performed within 14 days prior to day 1 of protocol therapy)
  • Creatinine =\< 2.5 mg/dL (to be performed within 14 days prior to day 1 of protocol therapy)

Exclusion criteria

Exclusion Criteria:

  • Prior radium Ra 223 dichloride
  • Prior or concomitant chemotherapy for or recurrent disease with the following exceptions:

    • Prior chemotherapy for local primary disease is permitted
    • Bisphosphonates or receptor activator of nuclear factor kappa-Β (RANK) ligand inhibitors are allowed at doses and schedule consistent with the treatment or prevention of osteoporosis
  • Prior radiation treatment for metastatic disease
  • Concomitant radiation treatment to primary prostate site
  • Orchiectomy
  • Unstable medical comorbidities (i.e. uncontrolled cardiac comorbidities)
  • Metastases that in the judgment of investigator-radiologist are not amenable to SBRT
  • History of or who currently have treated or untreated brain metastases
  • Uncontrolled (HIV) infection
  • Any other condition that would, in the investigator's judgement, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Treatment (hormone therapy, SBRT, radium Ra 223 dichloride)

    Beginning 4 weeks (28 days) prior to radiation therapy, patients receive leuprolide acetate or goserelin acetate, for up to 32 weeks. Patients also undergo 3-5 fractions of SBRT every 40 hours over 7-21 days beginning on day 1 of course 1, and receive radium Ra 223 dichloride IV over 1 minute on day 1 of courses 2-7. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity.

    Drug: Leuprolide Acetate · Drug: Goserelin Acetate · Radiation: Stereotactic Body Radiation Therapy · Radiation: Radium Ra 223 Dichloride · Other: Laboratory Biomarker Analysis · Drug: Degarelix

Interventions

  • DrugLeuprolideStudies of LeuprolideLeuprolide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intramuscular or subcutaneous injection

    Also known as: 377526, 6-D-Leucine-9-(N-ethyl-L-prolinamide)-1-9-luteinizing Hormone-releasing Factor (Pig) Monoacetate, 6-D-Leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig) Monoacetate, 74381-53-6, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur

  • DrugGoserelinStudies of GoserelinGoserelin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subcutaneous injection

    Also known as: 606864, 65807-02-5, D-Ser(bu(t))(6)azgly(10)-LHRH Acetate, ZDX, Zoladex

  • RadiationStereotactic Body Radiation Therapy

    Undergo SBRT

    Also known as: SABR, SBRT, Stereotactic Ablative Body Radiation Therapy

  • RadiationRadium Ra 223 Dichloride

    Given IV

    Also known as: 444811-40-9, Alpharadin, BAY 88-8223, BAY88-8223, Radium 223 Dichloride, RADIUM CHLORIDE RA-223, Radium-223 Dichloride, Xofigo

  • OtherLaboratory Biomarker Analysis

    Correlative studies

  • Subcutaneous injection

    Also known as: 214766-78-6, FE200486, Firmagon

06

What researchers measure

Primary outcomes

  1. Time to Treatment Failure

    Defined as time from the initiation of androgen deprivation therapy (ADT) for metastatic disease until PSA increase to \> pre-ADT level or PSA \> 10 (whichever is smaller) or radiographic or clinical progression or resumption of ADT by physician's choice.

    Time frame: Assessed up to 5 years

  2. Objective Response Rate

    Response will be evaluated in this study using the modified Prostate Cancer Working Group 2 criteria. Per Prostate Cancer Working Group 2 criteria for target lesions: Complete Response (CR), Disappearance of all target lesions. Lymph node CR is when the lymph node has decreased to less than 10mm in the short axis; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; For non-target lesions, CR: Disappearance of all non-target lesions and PSA level \<0.04 (undetectable). Overall Response (OR) = CR + PR. Proportion of patients achieving CR or PR at course 8, day 1 (post 6 doses of radium Ra 223 dichloride) were reported.

    Time frame: Up to 5 years

Secondary outcomes

  1. Progression-free Survival

    Progression will be evaluated in this study using the modified Prostate Cancer Working Group 2 criteria. Per Prostate Cancer Working Group 2 criteria for target lesions: Progressive Disease (PD), At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started (including the baseline scan if that is the smallest), and at least a 5mm increase or the appearance of new lesions; For non-target lesions, PD: Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. PSA increase by ≥ 25 % over baseline and to at least PSA \>2 ng/mL.

    Time frame: From the initiation of ADT for metastatic disease until PSA progression or radiographic progression or death, assessed up to 5 years

  2. Overall Survival

    Time frame: From date of initiation of protocol treatment to date of death from any cause, assessed up to 5 years

  3. Complete Response (CR) Rate Defined as the Proportion of Patients Achieving CR

    Response will be evaluated in this study using the modified Prostate Cancer Working Group 2 criteria. Per Prostate Cancer Working Group 2 criteria for target lesions: Complete Response (CR), Disappearance of all target lesions. Lymph node CR is when the lymph node has decreased to less than 10mm in the short axis; For non-target lesions, CR: Disappearance of all non-target lesions and PSA level \<0.04 (undetectable).

    Time frame: Up to 5 years

  4. Duration of Response

    Response will be evaluated in this study using modified Prostate Cancer Working Group 2 criteria.

    Time frame: From documented response to recurrent or progressive disease is first met, assessed up to 5 years

  5. Duration of Overall Complete Response

    Response will be evaluated in this study using modified Prostate Cancer Working Group 2 criteria.

    Time frame: From documented CR to recurrent/ progressive disease, assessed up to 5 years

  6. Bone Specific Progression-free Survival

    Progression will be evaluated in this study using modified Prostate Cancer Working Group 2 criteria. Progression will be evaluated in this study using the modified Prostate Cancer Working Group 2 criteria. Per Prostate Cancer Working Group 2 criteria for target lesions: Progressive Disease (PD), At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started (including the baseline scan if that is the smallest), and at least a 5mm increase or the appearance of new lesions; For non-target lesions, PD: Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. PSA increase by ≥ 25 % over baseline and to at least PSA \>2 ng/mL.

    Time frame: Time to progression of bone specific disease over baseline, assessed up to 5 years

  7. Duration of Stable Disease

    Response will be evaluated in this study using modified Prostate Cancer Working Group 2 criteria.

    Time frame: Time from start of treatment until the criteria for progression are met, taking as reference the smallest measurements recorded since the treatment started, assessed up to 5 years

  8. Number of Participants With Adverse Events (AE) Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0

    Toxicity will be graded. The highest AE grade per cycle will be reported in the electronic case report form (eCRF) from start of therapy until the end of treatment visit.

    Time frame: Up to 5 years

Other outcomes

  1. Rate of Normalization of the Total Alkaline Phosphatase Level

    The rate of normalization of the total alkaline phosphatase level (defined as a return to a value within the normal range) at the end of protocol therapy in patients with total alkaline phosphatase values above the upper limit of the normal range at baseline will be assessed.

    Time frame: Baseline up to 5 years

  2. Genomic Mutations Analysis

    Time frame: Up to 5 years

  3. Immune Biomarker Analysis

    Time frame: Up to 5 years

07

Results

Posted Apr 9, 2026

Participant flow

25 patients were enrolled between August 2018 and July 2023, including 6 de novo and 19 oligoprogressive mCSPC patients. 1 patient did not receive any cycles of Ra-223 and thus was excluded from analysis.

Participant flow — Overall Study
MilestoneDe Novo mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)Oligoprogressive mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)
Started618
Completed618
Not completed00

Outcome measures

PrimaryTime to Treatment Failure

Defined as time from the initiation of androgen deprivation therapy (ADT) for metastatic disease until PSA increase to \> pre-ADT level or PSA \> 10 (whichever is smaller) or radiographic or clinical progression or resumption of ADT by physician's choice.

Time frame:
Assessed up to 5 years
Reported as:
Median · months
Time to Treatment Failure
monthsDe Novo mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)Oligoprogressive mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)
Time to Treatment Failure42.1 (2.5 to NA)17.0 (13.1 to 21.7)
PrimaryObjective Response Rate

Response will be evaluated in this study using the modified Prostate Cancer Working Group 2 criteria. Per Prostate Cancer Working Group 2 criteria for target lesions: Complete Response (CR), Disappearance of all target lesions. Lymph node CR is when the lymph node has decreased to less than 10mm in the short axis; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; For non-target lesions, CR: Disappearance of all non-target lesions and PSA level \<0.04 (undetectable). Overall Response (OR) = CR + PR. Proportion of patients achieving CR or PR at course 8, day 1 (post 6 doses of radium Ra 223 dichloride) were reported.

Time frame:
Up to 5 years
Reported as:
Count of participants · Participants
Objective Response Rate
ParticipantsDe Novo mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)Oligoprogressive mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)
Objective Response Rate00
SecondaryProgression-free Survival

Progression will be evaluated in this study using the modified Prostate Cancer Working Group 2 criteria. Per Prostate Cancer Working Group 2 criteria for target lesions: Progressive Disease (PD), At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started (including the baseline scan if that is the smallest), and at least a 5mm increase or the appearance of new lesions; For non-target lesions, PD: Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. PSA increase by ≥ 25 % over baseline and to at least PSA \>2 ng/mL.

Time frame:
From the initiation of ADT for metastatic disease until PSA progression or radiographic progression or death, assessed up to 5 years
Reported as:
Median · months
Progression-free Survival
monthsDe Novo mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)Oligoprogressive mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)
Progression-free Survival42.1 (2.5 to NA)17.8 (13.1 to 23.0)
SecondaryOverall Survival
Time frame:
From date of initiation of protocol treatment to date of death from any cause, assessed up to 5 years
Reported as:
Median · months
Overall Survival
monthsDe Novo mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)Oligoprogressive mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)
Overall SurvivalNA (40.1 to NA)NA (47.2 to NA)
SecondaryComplete Response (CR) Rate Defined as the Proportion of Patients Achieving CR

Response will be evaluated in this study using the modified Prostate Cancer Working Group 2 criteria. Per Prostate Cancer Working Group 2 criteria for target lesions: Complete Response (CR), Disappearance of all target lesions. Lymph node CR is when the lymph node has decreased to less than 10mm in the short axis; For non-target lesions, CR: Disappearance of all non-target lesions and PSA level \<0.04 (undetectable).

Time frame:
Up to 5 years
Reported as:
Count of participants · Participants
Complete Response (CR) Rate Defined as the Proportion of Patients Achieving CR
ParticipantsDe Novo mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)Oligoprogressive mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)
Complete Response (CR) Rate Defined as the Proportion of Patients Achieving CR00
SecondaryDuration of Response

Response will be evaluated in this study using modified Prostate Cancer Working Group 2 criteria.

Time frame:
From documented response to recurrent or progressive disease is first met, assessed up to 5 years

No measurements were reported for this outcome.

SecondaryDuration of Overall Complete Response

Response will be evaluated in this study using modified Prostate Cancer Working Group 2 criteria.

Time frame:
From documented CR to recurrent/ progressive disease, assessed up to 5 years

No measurements were reported for this outcome.

SecondaryBone Specific Progression-free Survival

Progression will be evaluated in this study using modified Prostate Cancer Working Group 2 criteria. Progression will be evaluated in this study using the modified Prostate Cancer Working Group 2 criteria. Per Prostate Cancer Working Group 2 criteria for target lesions: Progressive Disease (PD), At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started (including the baseline scan if that is the smallest), and at least a 5mm increase or the appearance of new lesions; For non-target lesions, PD: Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. PSA increase by ≥ 25 % over baseline and to at least PSA \>2 ng/mL.

Time frame:
Time to progression of bone specific disease over baseline, assessed up to 5 years
Reported as:
Median · months
Bone Specific Progression-free Survival
monthsDe Novo mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)Oligoprogressive mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)
Bone Specific Progression-free Survival34.3 (2.5 to NA)NA (13.1 to NA)
SecondaryDuration of Stable Disease

Response will be evaluated in this study using modified Prostate Cancer Working Group 2 criteria.

Time frame:
Time from start of treatment until the criteria for progression are met, taking as reference the smallest measurements recorded since the treatment started, assessed up to 5 years
Reported as:
Median · months
Duration of Stable Disease
monthsDe Novo mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)Oligoprogressive mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)
Duration of Stable Disease49.9 (26.2 to NA)17.8 (13.1 to 23.0)
SecondaryNumber of Participants With Adverse Events (AE) Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0

Toxicity will be graded. The highest AE grade per cycle will be reported in the electronic case report form (eCRF) from start of therapy until the end of treatment visit.

Time frame:
Up to 5 years
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AE) Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
ParticipantsDe Novo mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)Oligoprogressive mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)
Number of Participants With Adverse Events (AE) Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0618
Other pre-specifiedRate of Normalization of the Total Alkaline Phosphatase Level

The rate of normalization of the total alkaline phosphatase level (defined as a return to a value within the normal range) at the end of protocol therapy in patients with total alkaline phosphatase values above the upper limit of the normal range at baseline will be assessed.

Time frame:
Baseline up to 5 years

Results for this outcome have not been posted.

Other pre-specifiedGenomic Mutations Analysis
Time frame:
Up to 5 years

Results for this outcome have not been posted.

Other pre-specifiedImmune Biomarker Analysis
Time frame:
Up to 5 years

Results for this outcome have not been posted.

Adverse events

Collected over Adverse events were assessed from the time of initial treatment until the end of treatment up to 5 years.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
De Novo mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)1/6 (16.7%)0/6 (0%)6/6 (100%)
Oligoprogressive mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)5/18 (27.8%)0/18 (0%)18/18 (100%)
Most frequent other events
Showing 10 of 118
Most frequent other events
EventDe Novo mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)Oligoprogressive mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)
HypertensionVascular disorders4/618/18
FatigueGeneral disorders3/613/18
AnemiaBlood and lymphatic system disorders4/612/18
White blood cell decreasedInvestigations4/612/18
HyperglycemiaMetabolism and nutrition disorders4/610/18
Sinus bradycardiaCardiac disorders2/610/18
DiarrheaGastrointestinal disorders3/69/18
Lymphocyte count decreasedInvestigations3/67/18
Platelet count decreasedInvestigations3/66/18
NauseaGastrointestinal disorders1/67/18

Baseline characteristics

Age, Continuous
Age, Continuous(years)De Novo mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)Oligoprogressive mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)Total
Median66 (61 to 83)70 (55 to 83)68 (55 to 83)
Sex: Female, Male
Sex: Female, Male(Participants)De Novo mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)Oligoprogressive mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)Total
Female000
Male61824
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)De Novo mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)Oligoprogressive mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)Total
African American011
Asian134
Hispanic/Latino134
White41014
Unknown011
Region of Enrollment
Region of Enrollment(participants)De Novo mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)Oligoprogressive mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)Total
United States61824
08

Study locations

1 site
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Mar 2024, 66 months.

Results were first posted in Apr 2026, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2017
First posted
Dec 5, 2017
StartActual
Aug 29, 2018
Primary completionActual
Mar 21, 2024
CompletionEst.
Jan 6, 2027
Results first posted
Apr 9, 2026
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03361735
Responsible party
Sponsor
First posted
Dec 5, 2017
Start date
Aug 29, 2018
Primary completion
Mar 21, 2024
Completion
Jan 6, 2027 (estimated)
Results posted
Apr 9, 2026
Last update
Apr 9, 2026

Study contacts

Savita Dandapani, MD
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Leuprolide · Goserelin · Degarelix

Start the discussion